COVID-19 Monoclonal Antibody Therapy

COVID-19 Monoclonal Antibody Therapy

To Submit a Referral for COVID-19 EUA Monoclonal Antibody Therapy:

  1. Click the Referral Link below to fill out the form
  2. Fax COVID positive lab results to (510) 969-5840
  3. Total Infusion will contact the patient directly to coordinate treatment (patients are contacted within 4 business hours and offered a same or next business day appointment)

Referral Link
Treatment Criteria
AT LEAST 12 YEARS OF AGE AND 88 POUNDS
AT LEAST ONE HIGH RISK CONDITION
ACTIVE INFECTION
COVID-19 Positive
(PCR or Rapid Antigen Test)
Onset of Mild to Moderate
Symptoms within 7 DAYS

Treatment Criteria

AT LEAST 12 YEARS OF AGE AND 88 POUNDS

AT LEAST ONE HIGH RISK CONDITION

ACTIVE INFECTION

COVID-19 Positive
(PCR or Rapid Antigen Test)

Onset of Mild to Moderate
Symptoms within 7 DAYS

HIGH RISK CONDITIONS
Other medical conditions or factors may also place individual patients at high risk for progression to severe COVID-19; authorization of REGEN-COV under the EUA is not limited to the medical conditions or factors listed below
Age > 65 of age Cardiovascular Disease/HTN
Overweight/Obesity (BMI>25) Sickle Cell Disease
Pregnancy/Postpartum (42 days) Neurodevelopmental Disorders
Chronic Kidney Disease Medical Related Technological Dependence
Diabetes Race/Ethnicity
Immunosuppressive Disease/Treatment Other Medical Conditions

HIGH RISK CONDITIONS
Other medical conditions or factors may also place individual patients at high risk for progression to severe COVID-19; authorization of REGEN-COV under the EUA is not limited to the medical conditions or factors listed below

Age > 65 of age

Cardiovascular Disease/HTN

Overweight/Obesity (BMI>25)

Sickle Cell Disease

Pregnancy/Postpartum (42 days)

Neurodevelopmental Disorders

Chronic Kidney Disease

Medical Related Technological Dependence

Diabetes

Race/Ethnicity

Immunosuppressive Disease/Treatment

Other Medical Conditions

PATIENTS ARE NOT ELIGIBLE FOR TREATMENT IF:
Hospitalized due to COVID-19
Require oxygen therapy due to COVID-19
Require an increase in baseline oxygen flow rate due to COVID-19 or for those on chronic oxygen therapy due to underlying non-COVID-19 related health issue

PATIENTS ARE NOT ELIGIBLE FOR TREATMENT IF:

Hospitalized due to COVID-19

Require oxygen therapy due to COVID-19

Require an increase in baseline oxygen flow rate due to COVID-19 or for those on chronic oxygen therapy due to underlying non-COVID-19 related health issue

FACT SHEET:
AUTHORIZED USE

Bebtelovimab is authorized for use under an Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Important Information About Bebtelovimab

Bebtelovimab is not FDA-approved and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Bebtelovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

LIMITATIONS OF AUTHORIZED USE:
  • Bebtelovimab is not authorized for use in patients:
    • who are hospitalized due to COVID-19, OR
    • who require oxygen therapy due to COVID-19, OR
    • who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity).
  • Benefit of treatment with Bebtelovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation.
VIEW THE FULL FACT SHEET FOR HEALTHCARE PROVIDERS
INFORMACIÓN EN ESPAÑOL

ADDRESS:

Eastmont Town Center 6955 Foothill Blvd, Suite 67A, Oakland, CA, 94605

BUSINESS HOURS:

Monday – Friday:

8:30am-5:00pm